Rekvina Laboratories (526075): Acquisition Analysis & Transformation Assessment

Executive Summary

Rekvina Laboratories has announced the allotment of 50.88 lakh equity shares at ₹10 per share to acquire 100% of Radiant Parenterals Limited for ₹4.63 crore via a share swap, alongside a ₹0.46 crore cash raise. This is a fundamental reverse-merger style transaction: Radiant Parenterals reported FY25 revenues of ₹31.67 crore, which is 31.7x Rekvina's standalone TTM revenue of ₹1.0 crore. The deal injects WHO-GMP and ISO certified manufacturing capabilities in injectables and syrups into Rekvina.

While the financial impact is transformative, significant governance and valuation considerations exist due to the equity deal price (₹10/share) being well below the pre-announcement market price (₹32.2/share), resulting in heavy share dilution.

1. Ramp-Aware Impact & Earnings Math

• Pre-Deal Financials: TTM Revenue of ₹1.00 Cr, FY26 Revenue of ₹1.27 Cr, Net Profit of -₹0.25 Cr (EPS -₹0.21).
• Target Financials: Radiant Parenterals FY25 Revenue of ₹31.67 Cr (up from ₹0.77 Cr in FY23).
• Share Capital Expansion:
• Existing Share Base: ~1.11 Cr shares.
• Allotment: 46.28 lakh shares for swap + 4.60 lakh shares for cash = 50.88 lakh new shares.
• Post-deal Share Base: ~1.62 Cr shares.
• Consolidated FY27 Estimates:
• Combined Revenue: ~₹33.0 Cr (Year-1 uplift of ~2,400%).
• Estimated NPM: Assuming standard formulation industry NPM of 8.0%, Consolidated PAT = ~₹2.64 Cr.
• Post-dilution Forward EPS: ₹2.64 Cr / 1.62 Cr shares = ₹1.63 per share.
• Valuation Context: At current price ₹32.2, implied forward P/E on FY27 earnings is ~19.8x, matching peer median trailing P/E (~14.5x - 20x).

2. Industry Context & Capital Intensity

• Industry: Indian Pharmaceutical Formulations / Injectables.
• Expected Industry CAGR: 10% - 12%.
• Capital Intensity: Medium. Facility is already operational and WHO-GMP certified in Vadodara.
• Execution Complexity: Moderate. Main risk is integration of financial controls and maintaining ongoing WHO-GMP quality compliance.

3. Governance & Quality Gate

• Quality Gate: FAILED on historical trailing data (ROCE -333%, Net Worth -₹1 Cr).
• Governance Concerns: 1. Preferential allotment at ₹10 per share while market price trades at ₹32.2 per share. 2. Micro-cap shell background with sparse operational history (< 8 quarters). 3. Pursuant to risk guidelines, presence of structural governance dilution caps confidence at 0.45 and verdict at POSSIBLE.

4. Calibrated Valuation Scenarios

• Bull Case (₹71.0 / +120%): Operational synergies push consolidated FY27 revenue to ₹40 Cr with 10% NPM (PAT ₹4.0 Cr; EPS ₹2.47). Stock re-rates to 28x forward P/E.
• Base Case (₹50.0 / +55%): Consolidated FY27 revenue reaches ₹33 Cr with 8% NPM (PAT ₹2.64 Cr; EPS ₹1.63). Stock trades at 30x forward P/E on turnaround.
• Bear Case (₹17.7 / -45%): Integration hurdles, working capital strain, or regulatory GMP audit issues keep NPM at 3% (PAT ₹1.0 Cr; EPS ₹0.61). Valuation contracts toward cash/book value.

5. Final Verdict Rationale

This deal represents a classic backdoor asset transformation. However, severe equity dilution at ₹10/share and poor historical trailing quality prevent a STRONG_CANDIDATE rating. Rekvina is rated POSSIBLE with a score of 58/100 and confidence of 0.45.